[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344858-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344858-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","neuroendocrine-neoplasms-of-the-esophagus-and-esophagogastric-junction-in-germany-20092023","Neuroendocrine Neoplasms of the Esophagus and Esophagogastric Junction in Germany, 2009–2023","","Background: Grading of esophageal neuroendocrine neoplasms (NENs) has been poorly assessed in small cohorts, limiting evidence on prognosis. Aim: Determine incidence and relative survival of esophageal NENs and subtypes across 2009–2023 in Germany. Methods: Incident cancers registered by German cancer registries were classified into NETs, neuroendocrine carcinomas (NECs), and mixed forms (MiNENs), with age-standardized incidence and 5-year relative survival using period analysis. Results: 69.9% were NECs, 19.5% NETs, and 10.7% MiNENs; prognosis differed strongly by grade. Conclusions: Even with diagnostic complexity, grading of esophageal NETs markedly influences survival. NECs show poorer outcomes than adenocarcinomas and squamous cell carcinomas.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/neuroendocrine-neoplasms-of-the-esophagus-and-esophagogastric-junction-in-germany-20092023/344858/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/neuroendocrine-neoplasms-of-the-esophagus-and-esophagogastric-junction-in-germany-20092023/344858.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study aim for esophageal neuroendocrine neoplasms?","Question",{"text":63,"@type":64},"To determine the incidence and relative survival of esophageal NENs and their subtypes, including how prognosis varies with grading, using Germany-wide registry data from 2009–2023.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the neuroendocrine neoplasms categorized in the study?",{"text":68,"@type":64},"They were subdivided into neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and mixed forms (MiNENs).",{"name":70,"@type":61,"acceptedAnswer":71},"What key finding did the study report about prognosis and grading?",{"text":72,"@type":64},"Grading of esophageal NETs strongly influenced prognosis, with NET-G1 showing the highest relative 5-year survival and NET-G3 the lowest.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344858,1790790172,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \nNeuroendocrine Neoplasms of the Esophagus and Esophagogastric Junction in Germany, 2009–2023  \nAndreas Stang 1,2, *, Ina Wellmann 2, Bernd Holleczek 3, Alice Nennecke 4, Guido Schumacher 5 and Hiltraud Kajüter 2  \nReceived: 29 December 2025  \nRevised: 2 February 2026  \nAccepted: 3 February 2026  \nPublished: 4 February 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Institute of Medical Informatics, Biometry, and Epidemiology, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany  \n2 Cancer Registry of North Rhine-Westphalia, Gesundheitscampus 10, 44801 Bochum, Germany; [ina.wellmann@krebsregister.nrw.de](ina.wellmann@krebsregister.nrw.de) (I.W.); [hiltraud.kajueter@krebsregister.nrw.de](hiltraud.kajueter@krebsregister.nrw.de) (H.K.)  \n3 Saarland Cancer Registry, Neugeländstr. 9, 66117 Saarbrücken, Germany; [b.holleczek@krebsregister.saarland.de](b.holleczek@krebsregister.saarland.de)  \n4 Hamburg Cancer Registry, Süderstr. 30, 20097 Hamburg, Germany; [alice.nennecke@bgv.hamburg.de](alice.nennecke@bgv.hamburg.de)  \n[5](5 Department of General Surgery)[ Department of General Surgery](5 Department of General Surgery), [Hospital of Brixen](Hospital of Brixen) ([SABES](SABES)), Dantestr. 51, 39042 Brixen, Italy; [guido.schumacher@sabes.it](guido.schumacher@sabes.it)  \n* Correspondence: imibe.dir@uk-essen.de; Tel.: +49-201-723-77-201  \nSimple Summary  \nUntil recently, the influence of the grading of neuroendocrine tumors (G1–G3) of the esophagus on prognosis could not be assessed due to limited data. We used all cancer registry data from Germany (population of 83 million people) in order to assemble the largest possible cohort of patients with these tumors and included 2025 newly diagnosed patients with esophageal or esophagogastric neuroendocrine neoplasms (394 neuroendocrine tumors (NET), 1415 neuroendocrine carcinomas, and 216 mixed neuroendocrine neoplasias in Germany 2009–2023 . In the survival analyses of 1320 neuroendocrine neoplasms, we found that the grading of NETs has a strong influence on prognosis. Patients with NET-G1 tumors hada relative 5-year survival of 83.8%, while patients with NET-G2 and NET-G3 tumors had relative survival of 50.0% and 9.0%, respectively. Relative 5-year survival was 12.5% and 25.3% for neuroendocrine carcinomas and mixed neuroendocrine neoplasms, respectively.  \nAbstract  \nBackground: The influence of the grading of esophageal neuroendocrine neoplasms (NENs) on prognosis has so far only been investigated in small groups. The aim was to determine the incidence and relative survival of NENs and its subtypes of the esophagus. Methods: We included incident cancers of the esophagus and esophagogastric junction (EGJ) for the years 2009–2023, registered by German cancer registries. NENs were subdivided into neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and mixed forms (MiNENs) . To compare the epidemiology of NENs with that of adenocarcinoma and squamous cell carcinoma, we also evaluated these entities in a statistically identical manner. We estimated age-standardized incidence rates (cases per million person-years, old European standard) and 5-year relative survival (period analysis) . Results: Of the 2025 NENs of the esophagus and EGJ, 69.9% were NECs, 19.5% were NETs, and 10.7% were MiNENs. 45.0% of NENs occurred at the EGJ. The mean age at diagnosis of esophageal NEN was 67 years. The age-standardized incidence of NEN and the subgroups increased over time, with NEN incidences of 1 . 1 and 0 .4 in 2019 and 2023 . Relative survival based on 1320 NENs was 22.8%, with NETs having a markedly better prognosis (59.8%) than NECs (12.5%) and MiNENs falling in between (25.3%) . Patients with NET-G1 tumors had a relative survival of 83.8%, while patients with NET-G2 and NET-G3 tumors had relative survival o","cbCaiotenYjUgTj4","https://ap.wps.com/l/cbCaiotenYjUgTj4","pdf",744466,12,"English","# Simple Summary\n# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# 1. Introduction","[{\"question\":\"What was the study aim for esophageal neuroendocrine neoplasms?\",\"answer\":\"To determine the incidence and relative survival of esophageal NENs and their subtypes, including how prognosis varies with grading, using Germany-wide registry data from 2009–2023.\"},{\"question\":\"How were the neuroendocrine neoplasms categorized in the study?\",\"answer\":\"They were subdivided into neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and mixed forms (MiNENs).\"},{\"question\":\"What key finding did the study report about prognosis and grading?\",\"answer\":\"Grading of esophageal NETs strongly influenced prognosis, with NET-G1 showing the highest relative 5-year survival and NET-G3 the lowest.\"}]","Neuroendocrine Neoplasms of the Esophagus and Esophagogastric Junction in Germany, 2009–2023 | PDF",1790055473,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9f5a0f00c71afce27c37c42100cbd4b.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68f11e1c584001f8959011684e85c1fb.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c828399990b1cf1e9c79bfa83f32f947.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/153bd34a0e95e64520f4a1de55bababb.webp",980,1385]